The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
ELCC 2017, was held in Geneva, Switzerland on 5-8 May, has attracted more than 2,500 participants including medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of patients with lung cancer. Immunotherapy and Liquid biopsy diagnostics are the hot topics this year.
As the leader of oncology diagnostics in China, AmoyDx introduced its innovative patented technology: Super-ARMS® to the visitors from all over the world. The technology was specifically developed for liquid biopsy samples with the advanced sensitivity, which can reach 0.2% for main target genes including EGFR. Meanwhile, AmoyDx ROS1 fusion detection kit drew a lot of attention in this event. The kit is CE and CFDA certified, and approved by Japanese authority (PMDA) as the only companion diagnostic kit for Crizotinib to identify patients who harbor ROS1 gene rearrangement.
In the future, AmoyDx will keep focusing on oncology diagnostics and make great effort to bring more and more benefits to cancer patients worldwide.
For further information on ELCC 2017, click here.